文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a)作为糖尿病患者和非糖尿病患者的心血管风险因素:麻省总医院布里格姆脂蛋白(a)登记处。

Lipoprotein(a) as a cardiovascular risk factor among patients with and without diabetes Mellitus: the Mass General Brigham Lp(a) Registry.

机构信息

Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

Cardiovasc Diabetol. 2024 Jul 18;23(1):257. doi: 10.1186/s12933-024-02348-2.


DOI:10.1186/s12933-024-02348-2
PMID:39026226
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11264681/
Abstract

BACKGROUND: Diabetes mellitus (DM) and Lp(a) are well-established predictors of coronary artery disease (CAD) outcomes. However, their combined association remains poorly understood. OBJECTIVE: To investigate the relationship between elevated Lp(a) and DM with CAD outcomes. METHODS: Retrospective analysis of the MGB Lp(a) Registry involving patients ≥ 18 years who underwent Lp(a) measurements between 2000 and 2019. Exclusion criteria were severe kidney dysfunction, malignant neoplasms, and prior atherosclerotic cardiovascular disease (ASCVD). The primary outcome was a combination of cardiovascular death or myocardial infarction (MI). Elevated Lp(a) was defined as > 90th percentile (≥ 216 nmol/L). RESULTS: Among 6,238 patients who met the eligibility criteria, the median age was 54, 45% were women, and 12% had DM. Patients with DM were older, more frequently male, and had a higher prevalence of additional cardiovascular risk factors. Over a median follow-up of 12.9 years, patients with either DM or elevated Lp(a) experienced higher rates of the primary outcome. Notably, those with elevated Lp(a) had a higher incidence of the primary outcome regardless of their DM status. The annual event rates were as follows: No-DM and Lp(a) < 90th% - 0.6%; No-DM and Lp(a) > 90th% - 1.3%; DM and Lp(a) < 90th% - 1.9%; DM and Lp(a) > 90th% - 4.7% (p < 0.001). After adjusting for confounders, elevated Lp(a) remained independently associated with the primary outcome among both patients with DM (HR = 2.66 [95%CI: 1.55-4.58], p < 0.001) and those without DM (HR = 2.01 [95%CI: 1.48-2.74], p < 0.001). CONCLUSIONS: Elevated Lp(a) constitutes an independent and incremental risk factor for CAD outcomes in patients with and without DM.

摘要

背景:糖尿病(DM)和脂蛋白(a)(Lp(a))是冠心病(CAD)结局的既定预测因素。然而,它们的联合相关性仍知之甚少。

目的:探讨升高的 Lp(a)与 DM 与 CAD 结局的关系。

方法:对 MGB Lp(a) 注册研究进行回顾性分析,该研究纳入了 2000 年至 2019 年期间接受 Lp(a)测量的年龄≥18 岁的患者。排除标准为严重肾功能不全、恶性肿瘤和既往动脉粥样硬化性心血管疾病(ASCVD)。主要结局是心血管死亡或心肌梗死(MI)的组合。升高的 Lp(a)定义为>第 90 百分位数(≥216nmol/L)。

结果:在符合入选标准的 6238 名患者中,中位年龄为 54 岁,45%为女性,12%患有 DM。患有 DM 的患者年龄更大,更常为男性,且存在更多的心血管危险因素。在中位随访 12.9 年后,无论 DM 状态如何,患有 DM 或升高的 Lp(a)的患者发生主要结局的比率更高。值得注意的是,无论 DM 状态如何,升高的 Lp(a)患者发生主要结局的发生率更高。每年的事件发生率如下:无 DM 和 Lp(a)<第 90 百分位数-0.6%;无 DM 和 Lp(a)>第 90 百分位数-1.3%;DM 和 Lp(a)<第 90 百分位数-1.9%;DM 和 Lp(a)>第 90 百分位数-4.7%(p<0.001)。在调整混杂因素后,升高的 Lp(a)在患有 DM 的患者(HR=2.66[95%CI:1.55-4.58],p<0.001)和无 DM 的患者(HR=2.01[95%CI:1.48-2.74],p<0.001)中与主要结局独立相关。

结论:升高的 Lp(a)是伴有或不伴有 DM 的 CAD 结局的独立且递增的危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e862/11264681/963b3a6fa648/12933_2024_2348_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e862/11264681/810f0abb79ce/12933_2024_2348_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e862/11264681/963b3a6fa648/12933_2024_2348_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e862/11264681/810f0abb79ce/12933_2024_2348_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e862/11264681/963b3a6fa648/12933_2024_2348_Fig2_HTML.jpg

相似文献

[1]
Lipoprotein(a) as a cardiovascular risk factor among patients with and without diabetes Mellitus: the Mass General Brigham Lp(a) Registry.

Cardiovasc Diabetol. 2024-7-18

[2]
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry.

J Am Heart Assoc. 2024-5-21

[3]
Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes.

Diabetes Care. 2019-5-10

[4]
Sex Differences in the Association Between Lipoprotein(a) and Cardiovascular Outcomes: The MGB Lp(a) Registry.

J Am Heart Assoc. 2025-5-6

[5]
Lack of association of serum lipoprotein (a) levels with type-2 diabetes mellitus in patients with angiographically defined coronary artery disease.

Int J Cardiol. 2000-7-31

[6]
Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity.

Eur J Prev Cardiol. 2024-5-11

[7]
Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus.

Nutr Metab Cardiovasc Dis. 2018-10

[8]
Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.

Am J Cardiol. 2016-12-15

[9]
Interaction between homocysteine and lipoprotein(a) increases the prevalence of coronary artery disease/myocardial infarction in women: a case-control study.

Thromb Res. 2011-7-30

[10]
Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease.

Cardiovasc Diabetol. 2020-3-19

引用本文的文献

[1]
Long-Term Impact of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation on Post-Acute Myocardial Infarction Long-Term All-Cause Mortality: Insights from the SAMI III Project.

J Clin Med. 2025-8-21

[2]
Lipoprotein (a) in primary cardiovascular disease prevention is actionable today.

Am Heart J Plus. 2025-7-21

[3]
Lp(a): Global Public Health Concern: Emerging Knowledge and Therapeutic Approaches.

Curr Cardiol Rep. 2025-6-25

[4]
Lipoprotein(a) and panvascular disease.

Lipids Health Dis. 2025-5-24

[5]
Lipoprotein(a) as a Risk Factor for Recurrent Ischemic Stroke in Type 2 Diabetes.

Diabetes Metab Syndr Obes. 2025-5-17

[6]
American society for preventive cardiology 2024 cardiovascular disease prevention: Highlights and key sessions.

Am J Prev Cardiol. 2024-12-15

[7]
Lipoprotein(a) and the atherosclerotic burden - Should we wait for clinical trial evidence before taking action?

Atheroscler Plus. 2024-9-26

本文引用的文献

[1]
Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry.

J Am Heart Assoc. 2024-5-21

[2]
Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.

J Am Coll Cardiol. 2024-4-23

[3]
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.

J Am Coll Cardiol. 2024-3-5

[4]
Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population.

Eur Heart J Open. 2023-8-27

[5]
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.

Circulation. 2024-1-16

[6]
Lipoprotein(a) as a Higher Residual Risk for Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus than without.

Int J Gen Med. 2023-8-8

[7]
Prognostic impacts of diabetes status and lipoprotein(a) levels in patients with ST-segment elevation myocardial infarction: a prospective cohort study.

Cardiovasc Diabetol. 2023-6-26

[8]
Lipoprotein(a) and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement.

JACC Asia. 2022-11-15

[9]
Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies.

J Clin Med. 2022-10-13

[10]
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.

Eur Heart J. 2022-10-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索